1
|
Onofre-Campos D, González-Trujano ME, Moreno-Pérez GF, Narváez-González F, González-Gómez JD, Villasana-Salazar B, Martínez-Vargas D. Anxiolytic-like Effects and Quantitative EEG Profile of Palmitone Induces Responses Like Buspirone Rather Than Diazepam as Clinical Drugs. Molecules 2023; 28:molecules28093680. [PMID: 37175090 PMCID: PMC10180017 DOI: 10.3390/molecules28093680] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Revised: 04/06/2023] [Accepted: 04/17/2023] [Indexed: 05/15/2023] Open
Abstract
Anxiety is a mental disorder with a growing worldwide incidence due to the SARS-CoV-2 virus pandemic. Pharmacological therapy includes drugs such as benzodiazepines (BDZs) or azapirones like buspirone (BUSP) or analogs, which unfortunately produce severe adverse effects or no immediate response, respectively. Medicinal plants or their bioactive metabolites are a shared global alternative to treat anxiety. Palmitone is one active compound isolated from Annona species due to its tranquilizing activity. However, its influence on neural activity and possible mechanism of action are unknown. In this study, an electroencephalographic (EEG) spectral power analysis was used to corroborate its depressant activity in comparison with the anxiolytic-like effects of reference drugs such as diazepam (DZP, 1 mg/kg) and BUSP (4 mg/kg) or 8-OH-DPAT (1 mg/kg), alone or in the presence of the GABAA (picrotoxin, PTX, 1 mg/kg) or serotonin 5-HT1A receptor antagonists (WAY100634, WAY, 1 mg/kg). The anxiolytic-like activity was assayed using the behavioral response of mice employing open-field, hole-board, and plus-maze tests. EEG activity was registered in both the frontal and parietal cortex, performing a 10 min baseline and 30 min recording after the treatments. As a result, anxiety-like behavior was significantly decreased in mice administered with palmitone, DZP, BUSP, or 8-OH-DPAT. The effect of palmitone was equivalent to that produced by 5-HT1A receptor agonists but 50% less effective than DZP. The presence of PTX and WAY prevented the anxiolytic-like response of DZP and 8-OH-DPAT, respectively. Whereas only the antagonist of the 5-HT1A receptor (WAY) inhibited the palmitone effects. Palmitone and BUSP exhibited similar changes in the relative power bands after the spectral power analysis. This response was different to the changes induced by DZP. In conclusion, brain electrical activity was associated with the anxiolytic-like effects of palmitone implying a serotoninergic rather than a GABAergic mechanism of action.
Collapse
Affiliation(s)
- Daniela Onofre-Campos
- Laboratorio de Neurofarmacología de Productos Naturales, Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Calz. México-Xochimilco 101, Col. San Lorenzo Huipulco, Tlalpan, Ciudad de México 14370, Mexico
- Biología Experimental, Universidad Autónoma Metropolitana, Ciudad de México 09340, Mexico
| | - María Eva González-Trujano
- Laboratorio de Neurofarmacología de Productos Naturales, Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Calz. México-Xochimilco 101, Col. San Lorenzo Huipulco, Tlalpan, Ciudad de México 14370, Mexico
| | - Gabriel Fernando Moreno-Pérez
- Laboratorio de Neurofarmacología de Productos Naturales, Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Calz. México-Xochimilco 101, Col. San Lorenzo Huipulco, Tlalpan, Ciudad de México 14370, Mexico
| | - Fernando Narváez-González
- ISSSTE Hospital Regional General Ignacio Zaragoza, Calz. Ignacio Zaragoza 1840, Juan Escutia, Iztapalapa, Ciudad de México 09100, Mexico
| | - José David González-Gómez
- Laboratorio de Neurofisiología del Control y la Regulación, Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Calz. México-Xochimilco 101, Col. San Lorenzo Huipulco, Tlalpan, Ciudad de México 14370, Mexico
| | - Benjamín Villasana-Salazar
- Laboratorio de Neurofisiología del Control y la Regulación, Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Calz. México-Xochimilco 101, Col. San Lorenzo Huipulco, Tlalpan, Ciudad de México 14370, Mexico
| | - David Martínez-Vargas
- Laboratorio de Neurofisiología del Control y la Regulación, Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Calz. México-Xochimilco 101, Col. San Lorenzo Huipulco, Tlalpan, Ciudad de México 14370, Mexico
| |
Collapse
|
2
|
Cunha A, Gaubert A, Verget J, Thiolat ML, Barthélémy P, Latxague L, Dehay B. Trehalose-Based Nucleolipids as Nanocarriers for Autophagy Modulation: An In Vitro Study. Pharmaceutics 2022; 14:857. [PMID: 35456691 PMCID: PMC9026460 DOI: 10.3390/pharmaceutics14040857] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Accepted: 04/08/2022] [Indexed: 01/03/2023] Open
Abstract
The Autophagy Lysosomal Pathway is one of the most important mechanisms for removing dysfunctional cellular components. Increasing evidence suggests that alterations in this pathway play a pathogenic role in Parkinson's disease, making it a point of particular vulnerability. Numerous studies have proposed nanotechnologies as a promising approach for delivering active substances within the central nervous system to treat and diagnose neurodegenerative diseases. In this context, the aim was to propose the development of a new pharmaceutical technology for the treatment of neurodegenerative diseases. We designed a trehalose-based nanosystem by combining both a small natural autophagy enhancer molecule named trehalose and an amphiphilic nucleolipid conjugate. To improve nucleolipid protection and cellular uptake, these conjugates were formulated by rapid mixing in either solid lipid nanoparticles (Ø = 120.4 ± 1.4 nm) or incorporated into poly(lactic-co-glycolic acid) nanoparticles (Ø = 167.2 ± 2.4 nm). In vitro biological assays demonstrated a safe and an efficient cellular uptake associated with autophagy induction. Overall, these nucleolipid-based formulations represent a promising new pharmaceutical tool to deliver trehalose and restore the autophagy impaired function.
Collapse
Affiliation(s)
- Anthony Cunha
- Univ. Bordeaux, INSERM U1212, CNRS UMR 5320, ARNA, ARN: Régulations Naturelle et Artificielle, ChemBioPharm, 146 rue Léo Saignat, F-33076 Bordeaux, France; (A.C.); (A.G.); (J.V.); (P.B.); (L.L.)
- Univ. Bordeaux, CNRS, IMN, UMR 5293, F-33000 Bordeaux, France;
| | - Alexandra Gaubert
- Univ. Bordeaux, INSERM U1212, CNRS UMR 5320, ARNA, ARN: Régulations Naturelle et Artificielle, ChemBioPharm, 146 rue Léo Saignat, F-33076 Bordeaux, France; (A.C.); (A.G.); (J.V.); (P.B.); (L.L.)
| | - Julien Verget
- Univ. Bordeaux, INSERM U1212, CNRS UMR 5320, ARNA, ARN: Régulations Naturelle et Artificielle, ChemBioPharm, 146 rue Léo Saignat, F-33076 Bordeaux, France; (A.C.); (A.G.); (J.V.); (P.B.); (L.L.)
| | | | - Philippe Barthélémy
- Univ. Bordeaux, INSERM U1212, CNRS UMR 5320, ARNA, ARN: Régulations Naturelle et Artificielle, ChemBioPharm, 146 rue Léo Saignat, F-33076 Bordeaux, France; (A.C.); (A.G.); (J.V.); (P.B.); (L.L.)
| | - Laurent Latxague
- Univ. Bordeaux, INSERM U1212, CNRS UMR 5320, ARNA, ARN: Régulations Naturelle et Artificielle, ChemBioPharm, 146 rue Léo Saignat, F-33076 Bordeaux, France; (A.C.); (A.G.); (J.V.); (P.B.); (L.L.)
| | - Benjamin Dehay
- Univ. Bordeaux, CNRS, IMN, UMR 5293, F-33000 Bordeaux, France;
| |
Collapse
|
3
|
Wang Y, Zhang R, Chen Q, Guo H, Liang X, Li T, Qi W, Xi L. Visualization of blood-brain barrier disruption with dual-wavelength high-resolution photoacoustic microscopy. BIOMEDICAL OPTICS EXPRESS 2022; 13:1537-1550. [PMID: 35415000 PMCID: PMC8973185 DOI: 10.1364/boe.449017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/18/2021] [Revised: 01/15/2022] [Accepted: 02/01/2022] [Indexed: 06/14/2023]
Abstract
The blood-brain barrier (BBB) strictly regulates the substance exchange between the vascular network and the central nervous system, and plays a critical role in maintaining normal brain homeostasis. Impaired BBB is often accompanied with the emergence of cerebral diseases and probably further leads to severe neuroinflammation or even neurological degeneration. Hence, there is an urgent need to precisely monitor the impaired BBB to understand its pathogenesis and better guide the enactment of therapeutic strategies. However, there is a lack of high-resolution imaging techniques to visualize and evaluate the large-scale BBB disruption in pre-clinical and clinical aspects. In this study, we propose a dual-wavelength photoacoustic imaging (PAI) methodology that simultaneously reveals the abnormal microvasculature and impaired BBB within the cerebral cortex. In in vivo studies, BBB disruption in both mice and rats were induced by local hot-water stimulation and unilateral carotid arterial perfusion of hyperosmolar mannitol, respectively. Subsequently, the exogenous contrast agent (CA) was injected into the microcirculation via the tail vein, and photoacoustic (PA) images of the microvasculature and leaked CA within the cerebral cortex were obtained by dual-wavelength photoacoustic microscopy to evaluate the BBB disruption. Besides, analysis of distribution and concentration of leaked CA in lesion region was further conducted to quantitatively reveal the dynamic changes of BBB permeability. Furthermore, we exploited this approach to investigate the reversibility of BBB disruption within the two distinct models. Based on the experimental results, this new proposed approach presents excellent performance in visualizing microvasculature and leaked CA, and enabling it possesses great potential in evaluating the abnormal microvasculature and impaired BBB result from cerebrovascular diseases.
Collapse
Affiliation(s)
- Yongchao Wang
- Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong, 518055, China
- These authors contributed equally to this study
| | - Ruoxi Zhang
- Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong, 518055, China
- These authors contributed equally to this study
| | - Qian Chen
- Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong, 518055, China
| | - Heng Guo
- Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong, 518055, China
| | - Xiao Liang
- Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong, 518055, China
| | - Tingting Li
- Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong, 518055, China
| | - Weizhi Qi
- Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong, 518055, China
- Shenzhen Bay Laboratory, Shenzhen, 518132, China
| | - Lei Xi
- Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong, 518055, China
| |
Collapse
|
4
|
Wang YC, Lu YB, Huang XL, Lao YF, Zhang L, Yang J, Shi M, Ma HL, Pan YW, Zhang YN. Myeloperoxidase: a new target for the treatment of stroke? Neural Regen Res 2022; 17:1711-1716. [PMID: 35017418 PMCID: PMC8820716 DOI: 10.4103/1673-5374.332130] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Myeloperoxidase is an important inflammatory factor in the myeloid system, primarily expressed in neutrophils and microglia. Myeloperoxidase and its active products participate in the occurrence and development of hemorrhagic and ischemic stroke, including damage to the blood-brain barrier and brain. As a specific inflammatory marker, myeloperoxidase can be used in the evaluation of vascular disease occurrence and development in stroke, and a large amount of experimental and clinical data has indicated that the inhibition or lack of myeloperoxidase has positive impacts on stroke prognosis. Many studies have also shown that there is a correlation between the overexpression of myeloperoxidase and the risk of stroke. The occurrence of stroke not only refers to the first occurrence but also includes recurrence. Therefore, myeloperoxidase is significant for the clinical evaluation and prognosis of stroke. This paper reviews the potential role played by myeloperoxidase in the development of vascular injury and secondary brain injury after stroke and explores the effects of inhibiting myeloperoxidase on stroke prognosis. This paper also analyzes the significance of myeloperoxidase etiology in the occurrence and development of stroke and discusses whether myeloperoxidase can be used as a target for the treatment and prediction of stroke.
Collapse
Affiliation(s)
- Yun-Chang Wang
- The Second Clinical Medical School, Lanzhou University; Department of Neurosurgery, Lanzhou University Second Hospital, Lanzhou, Gansu Province; Xiangya Hospital, Central South University, Changsha, Hunan Province, China
| | - Yu-Bao Lu
- The Second Clinical Medical School, Lanzhou University; Department of Neurosurgery, Lanzhou University Second Hospital, Lanzhou, Gansu Province; Department of Spine Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, China
| | - Xiao-Lan Huang
- University of Chinese Academy of Sciences, Beijing, China
| | - Yong-Feng Lao
- The Second Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China
| | - Lu Zhang
- The Second Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China
| | - Jun Yang
- The Second Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China
| | - Mei Shi
- The Second Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China
| | - Hai-Long Ma
- The Second Clinical Medical School, Lanzhou University, Lanzhou, Gansu Province, China
| | - Ya-Wen Pan
- The Second Clinical Medical School, Lanzhou University; Department of Neurosurgery, Lanzhou University Second Hospital, Lanzhou, Gansu Province, China
| | - Yi-Nian Zhang
- The Second Clinical Medical School, Lanzhou University; Department of Neurosurgery, Lanzhou University Second Hospital, Lanzhou, Gansu Province, China
| |
Collapse
|
5
|
Brouillard M, Barthélémy P, Dehay B, Crauste-Manciet S, Desvergnes V. Nucleolipid Acid-Based Nanocarriers Restore Neuronal Lysosomal Acidification Defects. Front Chem 2021; 9:736554. [PMID: 34490217 PMCID: PMC8417785 DOI: 10.3389/fchem.2021.736554] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2021] [Accepted: 08/06/2021] [Indexed: 01/08/2023] Open
Abstract
Increasing evidence suggests that lysosomal dysfunction has a pathogenic role in neurodegenerative diseases. In particular, an increase in lysosomal pH has been reported in different cellular models of Parkinson's disease. Thus, targeting lysosomes has emerged as a promising approach. More specifically, regulating its pH could play a central role against the neurodegeneration process. To date, only a few agents specifically targeting lysosomal pH are reported in the literature, partly due to the challenge of crossing the Blood-Brain-Barrier (BBB), preventing drug penetration into the central nervous system (CNS). To develop chronic treatments for neurodegenerative diseases, crossing the BBB is crucial. We report herein the conception and synthesis of an innovative DNA derivative-based nanocarrier. Nucleolipids, carrying a biocompatible organic acid as an active ingredient, were designed and synthesized as prodrugs. They were successfully incorporated into an oil-in-water nanoemulsion vehicle to cross biological membranes and then release effectively biocompatible acidic components to restore the functional lysosomal pH of neuronal cells. Biological assays on a genetic cell model of Parkinson's disease highlighted the non-toxicity of such nucleolipids after cellular uptake and their ability (at c = 40 µM) to fully restore lysosomal acidity.
Collapse
Affiliation(s)
| | | | - Benjamin Dehay
- University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux, France
| | - Sylvie Crauste-Manciet
- University of Bordeaux, INSERM U1212, UMR CNRS 5320, Bordeaux, France
- University Hospital, Bordeaux, France
| | | |
Collapse
|
6
|
Benizri S, Gaubert A, Soulard C, Gontier É, Svahn I, Rocchi P, Vacher G, Barthélémy P. Hydrogel based lipid-oligonucleotides: a new route to self-delivery of therapeutic sequences. Biomater Sci 2021; 9:3638-3644. [PMID: 33949449 DOI: 10.1039/d1bm00273b] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Synthetic OligoNucleotides (ON) provide promising therapeutic tools for controlling specifically genetic expression in a broad range of diseases from cancers to viral infections. Beside their chemical stability and intracellular delivery, the controlled release of therapeutic sequences remains an important challenge for successful clinical applications. In this work, Lipid-OligoNucleotide (LON) conjugates stabilizing hydrogels are reported and characterized by rheology and cryo-scanning electron microscopy (cryo-SEM). These studies revealed that lipid conjugation of antisense oligonucleotides featuring partial self-complementarity resulted in entangled pearl-necklace networks, which were obtained through micelle-micelle interaction driven by duplex formation. Owing to these properties, the Lipid AntiSense Oligonucleotide (LASO) sequences exhibited a prolonged release after subcutaneous administration compared to the non-lipidic antisense (ASO) one. The LASO self-assembly based hydrogels obtained without adjuvant represent an innovative approach for the sustained self-delivery of therapeutic oligonucleotides.
Collapse
Affiliation(s)
- Sébastien Benizri
- University of Bordeaux, INSERM U1212, UMR CNRS 5320, F-33076 Bordeaux, France.
| | - Alexandra Gaubert
- University of Bordeaux, INSERM U1212, UMR CNRS 5320, F-33076 Bordeaux, France.
| | - Charlotte Soulard
- University of Bordeaux, INSERM U1212, UMR CNRS 5320, F-33076 Bordeaux, France.
| | - Étienne Gontier
- Bordeaux Imaging Center, UMS3420 CNRS, University of Bordeaux, US4 INSERM, Bordeaux, France
| | - Isabelle Svahn
- Bordeaux Imaging Center, UMS3420 CNRS, University of Bordeaux, US4 INSERM, Bordeaux, France
| | - Palma Rocchi
- Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, Marseille, France
| | - Gaëlle Vacher
- University of Bordeaux, INSERM U1212, UMR CNRS 5320, F-33076 Bordeaux, France.
| | - Philippe Barthélémy
- University of Bordeaux, INSERM U1212, UMR CNRS 5320, F-33076 Bordeaux, France.
| |
Collapse
|
7
|
Kashapov R, Gaynanova G, Gabdrakhmanov D, Kuznetsov D, Pavlov R, Petrov K, Zakharova L, Sinyashin O. Self-Assembly of Amphiphilic Compounds as a Versatile Tool for Construction of Nanoscale Drug Carriers. Int J Mol Sci 2020; 21:E6961. [PMID: 32971917 PMCID: PMC7555343 DOI: 10.3390/ijms21186961] [Citation(s) in RCA: 44] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Revised: 09/18/2020] [Accepted: 09/19/2020] [Indexed: 12/12/2022] Open
Abstract
This review focuses on synthetic and natural amphiphilic systems prepared from straight-chain and macrocyclic compounds capable of self-assembly with the formation of nanoscale aggregates of different morphology and their application as drug carriers. Since numerous biological species (lipid membrane, bacterial cell wall, mucous membrane, corneal epithelium, biopolymers, e.g., proteins, nucleic acids) bear negatively charged fragments, much attention is paid to cationic carriers providing high affinity for encapsulated drugs to targeted cells. First part of the review is devoted to self-assembling and functional properties of surfactant systems, with special attention focusing on cationic amphiphiles, including those bearing natural or cleavable fragments. Further, lipid formulations, especially liposomes, are discussed in terms of their fabrication and application for intracellular drug delivery. This section highlights several features of these carriers, including noncovalent modification of lipid formulations by cationic surfactants, pH-responsive properties, endosomal escape, etc. Third part of the review deals with nanocarriers based on macrocyclic compounds, with such important characteristics as mucoadhesive properties emphasized. In this section, different combinations of cyclodextrin platform conjugated with polymers is considered as drug delivery systems with synergetic effect that improves solubility, targeting and biocompatibility of formulations.
Collapse
Affiliation(s)
- Ruslan Kashapov
- A.E. Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center of RAS, Arbuzov street 8, Kazan 420088, Russia; (G.G.); (D.G.); (D.K.); (R.P.); (K.P.); (L.Z.); (O.S.)
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Gabdrakhmanov DR, Kuznetsova DA, Saifina LF, Shulaeva MM, Semenov VE, Zakharova LY. Novel dicationic pyrimidine-based nucleolipid bearing piperidine head groups: Synthesis, aggregation behavior, solubilization capacity and interaction with DNA decamer. Colloids Surf A Physicochem Eng Asp 2020. [DOI: 10.1016/j.colsurfa.2020.124853] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
9
|
Cunha A, Prévot G, Mousli Y, Barthélémy P, Crauste-Manciet S, Dehay B, Desvergnes V. Synthesis and Intracellular Uptake of Rhodamine-Nucleolipid Conjugates into a Nanoemulsion Vehicle. ACS OMEGA 2020; 5:5815-5823. [PMID: 32226861 PMCID: PMC7097973 DOI: 10.1021/acsomega.9b03992] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/23/2019] [Accepted: 02/12/2020] [Indexed: 06/10/2023]
Abstract
Neurodegenerative diseases represent some of the greatest challenges for both basic science and clinical medicine. Due to their prevalence and the lack of known biochemical-based treatments, these complex pathologies result in an increasing societal cost. Increasing genetic and neuropathological evidence indicates that lysosomal impairment may be a common factor linking these diseases, demanding the development of therapeutic strategies aimed at restoring the lysosomal function. Here, we propose the design and synthesis of a nucleolipid conjugate as a nonviral chemical nanovector to specifically target neuronal cells and intracellular organelles. Herein, thymidine, appropriately substituted to increase its lipophilicity, was used as a model nucleoside and a fluorophore moiety, covalently bound to the nucleoside, allowed the monitoring of nucleolipid internalization in vitro. To improve nucleolipid protection and cellular uptake, these conjugates were formulated in nanoemulsions. In vitro biological assays demonstrated cell uptake- and internalization-associated colocalization with lysosomal markers. Overall, this nucleolipid-nanoemulsion-based formulation represents a promising drug-delivery tool to target the central nervous system, able to deliver drugs to restore the impaired lysosomal function.
Collapse
Affiliation(s)
- Anthony Cunha
- Université
de Bordeaux, INSERM, U1212, CNRS UMR 5320, ARNA, ARN: Régulations
Naturelle et Artificielle, ChemBioPharm, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France
- Université
de Bordeaux, Institut des Maladies Neurodégénératives,
UMR 5293, F-33076 Bordeaux, France
- CNRS,
Institut des Maladies Neurodégénératives, UMR
5293, Centre Broca Nouvelle-Aquitaine, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France
| | - Geoffrey Prévot
- Université
de Bordeaux, INSERM, U1212, CNRS UMR 5320, ARNA, ARN: Régulations
Naturelle et Artificielle, ChemBioPharm, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France
| | - Yannick Mousli
- Université
de Bordeaux, INSERM, U1212, CNRS UMR 5320, ARNA, ARN: Régulations
Naturelle et Artificielle, ChemBioPharm, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France
| | - Philippe Barthélémy
- Université
de Bordeaux, INSERM, U1212, CNRS UMR 5320, ARNA, ARN: Régulations
Naturelle et Artificielle, ChemBioPharm, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France
| | - Sylvie Crauste-Manciet
- Université
de Bordeaux, INSERM, U1212, CNRS UMR 5320, ARNA, ARN: Régulations
Naturelle et Artificielle, ChemBioPharm, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France
| | - Benjamin Dehay
- Université
de Bordeaux, Institut des Maladies Neurodégénératives,
UMR 5293, F-33076 Bordeaux, France
- CNRS,
Institut des Maladies Neurodégénératives, UMR
5293, Centre Broca Nouvelle-Aquitaine, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France
| | - Valérie Desvergnes
- Université
de Bordeaux, INSERM, U1212, CNRS UMR 5320, ARNA, ARN: Régulations
Naturelle et Artificielle, ChemBioPharm, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France
| |
Collapse
|